Cargando…
Collagenase Clostridium Histolyticum-aaes for Treatment of Cellulite: A Pooled Analysis of Two Phase-3 Trials
BACKGROUND: Collagen-rich fibrous septae and subcutaneous adipose protrusions play a role in cellulite pathophysiology. Collagenase clostridium histolyticum-aaes (CCH-aaes) injection causes enzymatic release of septae to resolve cellulite depressions and create a skin smoothing effect. This analysis...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132528/ https://www.ncbi.nlm.nih.gov/pubmed/35646496 http://dx.doi.org/10.1097/GOX.0000000000004306 |
_version_ | 1784713399295279104 |
---|---|
author | Bass, Lawrence S. Kaufman-Janette, Joely Joseph, John H. Kaminer, Michael S. Clark, James Fabi, Sabrina G. Gold, Michael H. Katz, Bruce E. Peddy, Kappa Schlessinger, Joel Young, V. Leroy Hurley, David McLane, Michael P. Vijayan, Saji Liu, Genzhou Davis, Matthew W. Goldman, Mitchel P. |
author_facet | Bass, Lawrence S. Kaufman-Janette, Joely Joseph, John H. Kaminer, Michael S. Clark, James Fabi, Sabrina G. Gold, Michael H. Katz, Bruce E. Peddy, Kappa Schlessinger, Joel Young, V. Leroy Hurley, David McLane, Michael P. Vijayan, Saji Liu, Genzhou Davis, Matthew W. Goldman, Mitchel P. |
author_sort | Bass, Lawrence S. |
collection | PubMed |
description | BACKGROUND: Collagen-rich fibrous septae and subcutaneous adipose protrusions play a role in cellulite pathophysiology. Collagenase clostridium histolyticum-aaes (CCH-aaes) injection causes enzymatic release of septae to resolve cellulite depressions and create a skin smoothing effect. This analysis pooled data from two identically designed, phase-3, randomized, double-blind, placebo-controlled studies to examine the efficacy and safety of CCH-aaes. METHODS: Adult women with moderate/severe cellulite (3–4 on Clinician Reported Photonumeric Cellulite Severity Scale and Patient Reported Photonumeric Cellulite Severity Scale) on the buttocks received up to three treatment sessions (Days 1, 22, and 43) of subcutaneous CCH-aaes 0.84 mg or placebo per treatment area. Composite and individual component response (≥2-level or ≥1-level improvement from baseline in Patient Reported Photonumeric Cellulite Severity Scale and/or Clinician Reported Photonumeric Cellulite Severity Scale) and additional patient-reported outcomes were determined at Day 71. RESULTS: Analysis included 424 CCH-aaes−treated and 419 placebo-treated women. CCH-aaes−treated women were 5.9 times more likely than placebo-treated women to be ≥2-level composite responders at Day 71 (odds ratio [95% confidence interval], 5.9 [2.2–15.4]; P < 0.001). A significantly greater percentage of CCH-aaes−treated women versus placebo-treated women were ≥1-level composite responders at Day 71 (39.4% versus 14.6%; P < 0.001). Subgroup analyses indicated no apparent impact of Fitzpatrick skin type category and baseline cellulite severity (moderate/severe) on CCH-aaes efficacy. An inverse relationship between age and CCH-aaes response was observed in those with a body mass index less than 32 kg per m(2). The most common adverse events with CCH-aaes were injection-site bruising and injection-site pain. CONCLUSION: CCH-aaes treatment significantly improved moderate-to-severe buttock cellulite appearance and was generally well tolerated. |
format | Online Article Text |
id | pubmed-9132528 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-91325282022-05-27 Collagenase Clostridium Histolyticum-aaes for Treatment of Cellulite: A Pooled Analysis of Two Phase-3 Trials Bass, Lawrence S. Kaufman-Janette, Joely Joseph, John H. Kaminer, Michael S. Clark, James Fabi, Sabrina G. Gold, Michael H. Katz, Bruce E. Peddy, Kappa Schlessinger, Joel Young, V. Leroy Hurley, David McLane, Michael P. Vijayan, Saji Liu, Genzhou Davis, Matthew W. Goldman, Mitchel P. Plast Reconstr Surg Glob Open Cosmetic BACKGROUND: Collagen-rich fibrous septae and subcutaneous adipose protrusions play a role in cellulite pathophysiology. Collagenase clostridium histolyticum-aaes (CCH-aaes) injection causes enzymatic release of septae to resolve cellulite depressions and create a skin smoothing effect. This analysis pooled data from two identically designed, phase-3, randomized, double-blind, placebo-controlled studies to examine the efficacy and safety of CCH-aaes. METHODS: Adult women with moderate/severe cellulite (3–4 on Clinician Reported Photonumeric Cellulite Severity Scale and Patient Reported Photonumeric Cellulite Severity Scale) on the buttocks received up to three treatment sessions (Days 1, 22, and 43) of subcutaneous CCH-aaes 0.84 mg or placebo per treatment area. Composite and individual component response (≥2-level or ≥1-level improvement from baseline in Patient Reported Photonumeric Cellulite Severity Scale and/or Clinician Reported Photonumeric Cellulite Severity Scale) and additional patient-reported outcomes were determined at Day 71. RESULTS: Analysis included 424 CCH-aaes−treated and 419 placebo-treated women. CCH-aaes−treated women were 5.9 times more likely than placebo-treated women to be ≥2-level composite responders at Day 71 (odds ratio [95% confidence interval], 5.9 [2.2–15.4]; P < 0.001). A significantly greater percentage of CCH-aaes−treated women versus placebo-treated women were ≥1-level composite responders at Day 71 (39.4% versus 14.6%; P < 0.001). Subgroup analyses indicated no apparent impact of Fitzpatrick skin type category and baseline cellulite severity (moderate/severe) on CCH-aaes efficacy. An inverse relationship between age and CCH-aaes response was observed in those with a body mass index less than 32 kg per m(2). The most common adverse events with CCH-aaes were injection-site bruising and injection-site pain. CONCLUSION: CCH-aaes treatment significantly improved moderate-to-severe buttock cellulite appearance and was generally well tolerated. Lippincott Williams & Wilkins 2022-05-25 /pmc/articles/PMC9132528/ /pubmed/35646496 http://dx.doi.org/10.1097/GOX.0000000000004306 Text en Copyright © 2022 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Cosmetic Bass, Lawrence S. Kaufman-Janette, Joely Joseph, John H. Kaminer, Michael S. Clark, James Fabi, Sabrina G. Gold, Michael H. Katz, Bruce E. Peddy, Kappa Schlessinger, Joel Young, V. Leroy Hurley, David McLane, Michael P. Vijayan, Saji Liu, Genzhou Davis, Matthew W. Goldman, Mitchel P. Collagenase Clostridium Histolyticum-aaes for Treatment of Cellulite: A Pooled Analysis of Two Phase-3 Trials |
title | Collagenase Clostridium Histolyticum-aaes for Treatment of Cellulite: A Pooled Analysis of Two Phase-3 Trials |
title_full | Collagenase Clostridium Histolyticum-aaes for Treatment of Cellulite: A Pooled Analysis of Two Phase-3 Trials |
title_fullStr | Collagenase Clostridium Histolyticum-aaes for Treatment of Cellulite: A Pooled Analysis of Two Phase-3 Trials |
title_full_unstemmed | Collagenase Clostridium Histolyticum-aaes for Treatment of Cellulite: A Pooled Analysis of Two Phase-3 Trials |
title_short | Collagenase Clostridium Histolyticum-aaes for Treatment of Cellulite: A Pooled Analysis of Two Phase-3 Trials |
title_sort | collagenase clostridium histolyticum-aaes for treatment of cellulite: a pooled analysis of two phase-3 trials |
topic | Cosmetic |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132528/ https://www.ncbi.nlm.nih.gov/pubmed/35646496 http://dx.doi.org/10.1097/GOX.0000000000004306 |
work_keys_str_mv | AT basslawrences collagenaseclostridiumhistolyticumaaesfortreatmentofcelluliteapooledanalysisoftwophase3trials AT kaufmanjanettejoely collagenaseclostridiumhistolyticumaaesfortreatmentofcelluliteapooledanalysisoftwophase3trials AT josephjohnh collagenaseclostridiumhistolyticumaaesfortreatmentofcelluliteapooledanalysisoftwophase3trials AT kaminermichaels collagenaseclostridiumhistolyticumaaesfortreatmentofcelluliteapooledanalysisoftwophase3trials AT clarkjames collagenaseclostridiumhistolyticumaaesfortreatmentofcelluliteapooledanalysisoftwophase3trials AT fabisabrinag collagenaseclostridiumhistolyticumaaesfortreatmentofcelluliteapooledanalysisoftwophase3trials AT goldmichaelh collagenaseclostridiumhistolyticumaaesfortreatmentofcelluliteapooledanalysisoftwophase3trials AT katzbrucee collagenaseclostridiumhistolyticumaaesfortreatmentofcelluliteapooledanalysisoftwophase3trials AT peddykappa collagenaseclostridiumhistolyticumaaesfortreatmentofcelluliteapooledanalysisoftwophase3trials AT schlessingerjoel collagenaseclostridiumhistolyticumaaesfortreatmentofcelluliteapooledanalysisoftwophase3trials AT youngvleroy collagenaseclostridiumhistolyticumaaesfortreatmentofcelluliteapooledanalysisoftwophase3trials AT hurleydavid collagenaseclostridiumhistolyticumaaesfortreatmentofcelluliteapooledanalysisoftwophase3trials AT mclanemichaelp collagenaseclostridiumhistolyticumaaesfortreatmentofcelluliteapooledanalysisoftwophase3trials AT vijayansaji collagenaseclostridiumhistolyticumaaesfortreatmentofcelluliteapooledanalysisoftwophase3trials AT liugenzhou collagenaseclostridiumhistolyticumaaesfortreatmentofcelluliteapooledanalysisoftwophase3trials AT davismattheww collagenaseclostridiumhistolyticumaaesfortreatmentofcelluliteapooledanalysisoftwophase3trials AT goldmanmitchelp collagenaseclostridiumhistolyticumaaesfortreatmentofcelluliteapooledanalysisoftwophase3trials |